BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,798 shares of the biotechnology company’s stock after acquiring an additional 379 shares during the period. Daiwa Securities Group Inc.’s holdings in BioMarin Pharmaceutical were worth $1,909,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its stake in BioMarin Pharmaceutical by 7,368.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 60,571 shares of the biotechnology company’s stock valued at $5,840,000 after acquiring an additional 59,760 shares during the period. EFG Asset Management North America Corp. lifted its stake in BioMarin Pharmaceutical by 44.9% during the 3rd quarter. EFG Asset Management North America Corp. now owns 67,322 shares of the biotechnology company’s stock valued at $5,957,000 after acquiring an additional 20,874 shares during the period. International Assets Investment Management LLC acquired a new stake in BioMarin Pharmaceutical during the 4th quarter valued at approximately $3,598,000. FMR LLC lifted its stake in BioMarin Pharmaceutical by 30.4% during the 3rd quarter. FMR LLC now owns 713,797 shares of the biotechnology company’s stock valued at $63,157,000 after acquiring an additional 166,219 shares during the period. Finally, Nordea Investment Management AB lifted its stake in shares of BioMarin Pharmaceutical by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 11,594 shares of the biotechnology company’s stock valued at $1,121,000 after purchasing an additional 544 shares during the period. 98.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BMRN shares. Robert W. Baird decreased their target price on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating for the company in a research note on Tuesday, January 30th. Canaccord Genuity Group reiterated a “hold” rating and issued a $91.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Piper Sandler cut their price target on shares of BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, February 23rd. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $107.61.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, Director Jean Jacques Bienaime sold 20,000 shares of the company’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $91.26, for a total value of $1,825,200.00. Following the transaction, the director now owns 474,994 shares of the company’s stock, valued at $43,347,952.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other BioMarin Pharmaceutical news, Director Jean Jacques Bienaime sold 20,000 shares of the company’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $91.26, for a total value of $1,825,200.00. Following the transaction, the director now owns 474,994 shares of the company’s stock, valued at $43,347,952.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Erin Burkhart sold 2,286 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $90.00, for a total transaction of $205,740.00. Following the completion of the transaction, the chief accounting officer now directly owns 16,156 shares in the company, valued at approximately $1,454,040. The disclosure for this sale can be found here. Insiders have sold 103,229 shares of company stock valued at $9,062,967 over the last 90 days. 1.84% of the stock is owned by insiders.

BioMarin Pharmaceutical Trading Up 1.0 %

Shares of BMRN opened at $89.49 on Tuesday. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12. BioMarin Pharmaceutical Inc. has a 12-month low of $76.02 and a 12-month high of $99.56. The firm has a 50-day moving average price of $87.64 and a 200 day moving average price of $89.18. The firm has a market capitalization of $16.89 billion, a P/E ratio of 101.69, a P/E/G ratio of 1.64 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The firm had revenue of $646.21 million during the quarter, compared to analyst estimates of $639.53 million. During the same quarter in the prior year, the firm posted $0.11 earnings per share. BioMarin Pharmaceutical’s quarterly revenue was up 20.2% on a year-over-year basis. Sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 1.85 EPS for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.